for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Flexion Therapeutics Inc

FLXN.OQ

Latest Trade

11.65USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

5.01

 - 

22.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Flexion Therapeutics Announces Pricing Of Public Offering Of Common Stock

May 21 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.23 MILLION COMMON SHARES PRICED AT $9.75PER SHARE.

Flexion Therapeutics Announces Proposed Public Offering Of Common Stock

May 20 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.FLEXION THERAPEUTICS INC SAYS COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $75.0 MILLION OF SHARES OF ITS COMMON STOCK.

Flexion Enters Into Amendment To Credit And Security Agreement

May 19 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS INC - ON MAY 18, ENTERED INTO AN AMENDMENT TO OUR CREDIT AND SECURITY AGREEMENT.FLEXION THERAPEUTICS INC - PURSUANT TO AMENDMENT, WE BORROWED $15.0 MILLION UNDER A NEW TERM LOAN ADVANCE.FLEXION THERAPEUTICS INC - IMMEDIATELY USED PROCEEDS TO REPAY AN EQUAL AMOUNT UNDER OUR REVOLVING CREDIT FACILITY.FLEXION THERAPEUTICS INC - MAXIMUM PRINCIPAL AMOUNT OF REVOLVING CREDIT FACILITY WAS REDUCED FROM $20.0 MILLION TO $5.0 MILLION.FLEXION THERAPEUTICS INC - AT MARCH 31, 2020, TOTAL LIQUIDITY AS DETERMINED UNDER CREDIT AND SECURITY AGREEMENT FOLLOWING AMENDMENT WAS $157.2 MILLION.FLEXION THERAPEUTICS INC - CONTINUE TO EXPECT TO EXPERIENCE A MATERIAL DECLINE IN REVENUES FOR REMAINDER OF 2020, AND POSSIBLY LONGER.

Flexion Therapeutics Announces Zilretta License Agreement And Provides Business Update Amid Coronavirus Pandemic

April 1 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES ZILRETTA® LICENSE AGREEMENT AND PROVIDES BUSINESS UPDATE AMID CORONAVIRUS PANDEMIC.FLEXION THERAPEUTICS - AGREEMENT PROVIDES CO WITH $10 MILLION UPFRONT PAYMENT, UP TO $32.5 MILLION IN MILESTONES, AND ADDITIONAL FEES FOR SUPPLY OF ZILRETTA.FLEXION THERAPEUTICS INC - WITHDRAWS 2020 ZILRETTA REVENUE GUIDANCE DUE TO IMPACT OF CORONAVIRUS GLOBAL PANDEMIC.FLEXION THERAPEUTICS INC - TO TEMPORARILY SUSPEND CLINICAL TRIALS FOR ZILRETTA AND FX201; FX301 PRECLINICAL ACTIVITIES CONTINUE TO ADVANCE.FLEXION THERAPEUTICS INC - LICENSE AGREEMENT WITH HK TAINUO AND JIANGSU TAINUO FOR DEVELOPMENT AND COMMERCIALIZATION OF ZILRETTA.

Flexion Therapeutics Reports Fourth-Quarter Results

March 12 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS.FLEXION THERAPEUTICS INC - AS OF DECEMBER 31, 2019, CO HAD APPROXIMATELY $136.7 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES.

Flexion Therapeutics Announces Preliminary Q4 Revenue And 2019 Outlook

Jan 9 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH-QUARTER AND FULL-YEAR 2019 REVENUE AND INITIAL REVENUE GUIDANCE FOR 2020.SEES FY 2019 REVENUE $73 MILLION.SEES Q4 2019 REVENUE $23.7 MILLION.FLEXION PROVIDES 2020 PRODUCT REVENUE GUIDANCE OF $120 MILLION TO $135 MILLION.FY2019 REVENUE VIEW $73.4 MILLION -- REFINITIV IBES DATA.Q4 REVENUE VIEW $24.2 MILLION -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $133.2 MILLION -- REFINITIV IBES DATA.

Flexion Therapeutics Announces FDA Approval To Revise Zilretta Product Label

Dec 26 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES FDA APPROVAL OF SNDA TO REVISE ZILRETTA® (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) PRODUCT LABEL.FLEXION THERAPEUTICS - LABEL UPDATE INCLUDES REMOVAL OF LANGUAGE WHICH STATED THAT ZILRETTA WAS "NOT INTENDED FOR REPEAT ADMINISTRATION".FLEXION THERAPEUTICS - LABEL UPDATE INCLUDES INCLUSION OF STUDY DESCRIPTION, SAFETY DATA FROM SINGLE-ARM, OPEN-LABEL PHASE 3 REPEAT TRIAL.FLEXION THERAPEUTICS - LABEL UPDATE INCLUDES REMOVAL OF "MISLEADING STATEMENT" DESCRIBING SINGLE SECONDARY ENDPOINT IN ORIGINAL PHASE 3 TRIAL.FLEXION THERAPEUTICS - LABEL UPDATE INCLUDES INCLUSION OF NONCLINICAL TOXICOLOGY DATA FROM PREVIOUSLY SUBMITTED STUDIES IN NON-DISEASED ANIMALS.

Flexion Therapeutics Announces The Retirement Of Chief Scientific Officer And Company Co-Founder, Neil Bodick

Dec 10 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES THE RETIREMENT OF NEIL BODICK, M.D., PH.D., CHIEF SCIENTIFIC OFFICER AND COMPANY CO-FOUNDER.FLEXION THERAPEUTICS - FOLLOWING BODICK'S RETIREMENT IN JANUARY, HE WILL CONTINUE IN A CONSULTING ROLE.

Flexion Therapeutics Posts Q3 Sales $21.8 Mln Vss IBES Estimate Of $19 Mln

Nov 7 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS THIRD-QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q3 SALES $21.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $19 MILLION.AS OF SEPTEMBER 30, CO HAD ABOUT $175.8 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES.QTRLY LOSS PER SHARE $1.Q3 EARNINGS PER SHARE VIEW $-0.96, REVENUE VIEW $19.0 MILLION -- REFINITIV IBES DATA.TIGHTENING FY 2019 ZILRETTA NET SALES GUIDANCE TO $70 MILLION TO $75 MILLION.

Flexion Therapeutics Receives Fda Clearance Of Investigational New Drug Application For Gene Therapy Candidate Fx201

Oct 31 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES FDA CLEARANCE OF THE INVESTIGATIONAL NEW DRUG APPLICATION FOR FX201, A GENE THERAPY CANDIDATE FOR THE TREATMENT OF OSTEOARTHRITIS.FLEXION THERAPEUTICS INC - PHASE 1 STUDY IS EXPECTED TO BEGIN ENROLLING BY YEAR-END WITH INITIAL CLINICAL DATA ANTICIPATED IN 2021.FLEXION THERAPEUTICS - HAS INITIATED PHASE 1 MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY & EXPECTS TO TREAT FIRST PATIENT BY END OF THIS YEAR.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up